

#19/D  
gnd  
10/7/02



Attorney Docket No. 46963-DIV (71417)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT Isner, et al. EXAMINER: Gambel, Phillip  
U.S.S.N.: 09/228,020 GROUP: 1644  
FILED: January 11, 1999 Conf. No. 7379  
FOR: METHODS FOR REGULATING ANGIOGENESIS

**RECEIVED**

SEP 26 2002

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, DC 20231

**AMENDMENT AND RESPONSE TO ELECTION OF SPECIES REQUIREMENT**

This paper is responsive to the Election of Species Requirement mailed April 17, 2002.  
Please amend the subject application as follows:

**In The Claims**

✓✓✓✓✓✓  
Please **cancel** claims 1-19, 21, 22, 40, 43, and 48-64 without prejudice.

Please **amend** claims 20, as follows.

DI

20. (Amended) A pharmaceutical product comprising a nucleic acid encoding an endothelial cell mitogen and endothelial cell (EC) progenitors, in a physiologically acceptable administrable form, wherein the EC progenitors are CD34<sup>+</sup>, Flk-1<sup>+</sup>, and tie-2<sup>+</sup>.

51